NIH Guide: Weekly Index for October 1, 2021

Funding Opportunities

• Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)
  (PAR-21-344)
  John E. Fogarty International Center
  National Cancer Institute
  National Institute on Drug Abuse
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  Application Receipt Date(s): December 20, 2022
• Limited Competition: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)
  (PAR-21-346)
  National Cancer Institute
  Application Receipt Date(s): November 17, 2021
• The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)
  (PAR-21-348)
  National Cancer Institute
  Application Receipt Date(s): December 15, 2023
• NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)
  (PAR-21-351)
  National Institute on Aging
  Application Receipt Date(s): February 12, 2022 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed)
  (PAR-22-021)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): Multiple dates, see announcement.
• Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)
  (PAR-22-037)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): February 4, 2022
• Systems Biology for Infectious Diseases (U19 Clinical Trial Not Allowed)
  (RFA-AI-21-065)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): January 14, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date
• HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed)
  (RFA-HL-22-013)
  National Heart, Lung, and Blood Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): December 3, 2021
• Advancing Gender Inclusive Excellence (AGIE) Coordinating Center (U54 Clinical Trial Not Allowed)
  (RFA-OD-21-010)
  Office of Research on Women's Health
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): November 30, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this Funding Opportunity Announcement.